More recently, the effect of BiTEs targeting carcinoembryonic antigen (CEA) was studied in a Phase I clinical trial on patients with gastrointestinal adenocarcinomas, including pancreatic cancer (71, 85). Here, CEACAM5 is linked to familial pancreatic carcinoma.